Clinical trials: Pulmonary Artery Hypertension
Systemic Sclerosis, Pulmonary Hypertension
Evaluating Lung Doppler Signals in Patients With Systemic Sclerosis (SSc)
Doppler signals can be recorded from the lung parenchyma by means of a pulsed Doppler ultrasound system incorporating a special signal processing package; i.e.
- Trial name
- NCT02246348
- Testing
- Doppler ultrasound
- Where
- Israel
- Volunteers
- 5 people
- Sponsor
- Echosense Ltd.
Pulmonary Hypertension
Efficacy and Safety of Upfront Combination of ΒΟsentan and ΤΑdalafil in Pulmonary Arterial Hypertension
The development of disease-targeted drugs for the treatment of pulmonary arterial hypertension (PAH) has significantly improved within the last years.
- Trial name
- BOTA-PAH (NCT03139084)
- Sponsor
- Elpen Pharmaceutical Co. Inc.
Pulmonary Arterial Hypertension
Study of Intravenous Remodulin in Patients in India With Pulmonary Arterial Hypertension
Multi-center, double-blind, placebo-controlled, randomized, parallel study comparing continuous intravenous (IV) Remodulin® to placebo in patients with pulmonary arterial hypertension either primary (PPH) or associated with human…
- Trial name
- TRUST-1 (NCT00494533)
- Testing
- Remodulin (treprostinil sodium)
- Where
- 14 sites in India
- Volunteers
- 45 people
- Sponsor
- United Therapeutics
Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH), Pulmonary Arterial Hypertension (PAH)
imprOving Adherence to Pulmonary artErial hyperteNsion Treatment With teLemedicIne and patieNt guidaNce
Pulmonary arterial hypertension (PAH) is a progressive condition with high morbidity, frequent hospitalizations, and risk of right heart failure. Despite advances in treatment, poor adherence remains a major challenge.
- Conditions
- Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH), Pulmonary Arterial Hypertension (PAH), Pulmonary Arterial Hypertension
- Trial name
- OPENLINE (NCT06850792)
- Testing
- Telemedicine-Based Adherence Support
- Where
- Brazil
- Volunteers
- 61 people
- Sponsor
- University of Sao Paulo General Hospital
Hereditary Hemorrhagic Telangiectasia, Pulmonary Arterial Hypertension
DIAG723 in Adults With Hereditary Hemorrhagic Telangiectasia
This is a Phase 1/2, randomized, double-blind, placebo-controlled, first-in-human study evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of subcutaneously administered DIAG723 in adult patients with…
- Trial name
- DIAMOND (NCT07623525)
- Testing
- DIAG723
- Where
- 11 sites in Australia, Canada and 1 more
- Volunteers
- 93 people
- Sponsor
- Diagonal Therapeutics, Inc.
Pulmonary Arterial Hypertension, HIV Infection
Auto-immunity and Pulmonary Arterial Hypertension
The investigators have recently evidenced the presence of antibodies to endothelial cells and fibroblasts in patients with idiopathic or SSc-associated PAH.
- Conditions
- Pulmonary Arterial Hypertension, HIV Infection, Congenital Heart Defect, Systemic Sclerosis
- Trial name
- Auto-HTAP (NCT01208792)
- Testing
- skin biopsy, Blood Sample
- Where
- 3 sites in France
- Volunteers
- 629 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Pulmonary Vascular Disease, Pulmonary Artery Hypertension
High Altitude (HA) Residents With Pulmonary Vascular Diseases (PVD), 6 Minute Walk Distance (6MWD) Assessed at 2840m (HA) With and Without Supplemental Oxygen Therapy (SOT)
The investigators aim to study the effect of SOT in participants with pulmonary vascular diseases (PVD) defined as pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension (PH) who permanently live >2500m…
- Conditions
- Pulmonary Vascular Disease, Pulmonary Artery Hypertension, Chronic Thromboembolic Pulmonary Hypertension
- Trial name
- NCT06003244
- Testing
- 6-minute walk distance (6MWD) test, 6-minute walk distance (6MWD) test with supplemental oxygen (3 l/min, nasal)
- Where
- Switzerland
- Volunteers
- 24 people
- Sponsor
- University of Zurich
Pulmonary Arterial Hypertension
Pulmonary Vascular Disease Phenomics Program PVDOMICS
It is recognized that patients with various forms of heart and lung disease exhibit varying degrees of pulmonary hypertension, pulmonary vascular remodeling, and right ventricular dysfunction.
- Trial name
- PVDOMICS (NCT02980887)
- Testing
- No Intervention
- Where
- 7 sites in United States
- Volunteers
- 1,195 people, healthy volunteers welcome
- Sponsor
- The Cleveland Clinic
Pulmonary Arterial Hypertension
Dysregulation of Lipid Metabolism and Right Ventricular Function in PAH
Right ventricular (RV) failure is the predominant cause of death in pulmonary arterial hypertension (PAH). No RV-specific therapies are available, in part because the underlying mechanisms of RV dysfunction are poorly understood.
- Trial name
- NCT02631421
- Testing
- Blood Sampling, Cardiac MRI
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Vanderbilt University
Pulmonary Arterial Hypertension
Prevalence of Musculoskeletal Pain and Its Impact on Quality of Life and Functional Exercise Capacity in Patients With Pulmonary Arterial Hypertension
Prevalence of musculoskeletal pain and its impact of quality of life and functional exercise capacity will be evaluated in patients with pulmonary arterial hypertension.
- Trial name
- NCT04808830
- Testing
- Evaluation of musculoskeletal pain prevalence, Evaluation of quality of life, Evaluation of functional exercise capacity
- Where
- Turkey (Türkiye)
- Volunteers
- 61 people
- Sponsor
- Izmir Bakircay University
Pulmonary Arterial Hypertension
Oral CXA-10 in Pulmonary Arterial Hypertension
The main objective of this study is to evaluate the safety and tolerability of 12-week oral CXA-10 therapy in subjects with pulmonary arterial hypertension, with additional evaluation on the clinical efficacy of oral CXA-10 on…
- Trial name
- PAH (NCT04125745)
- Testing
- CXA-10
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Gladwin, Mark, MD
Pulmonary Arterial Hypertension
National Registry and Cohort Study of Pulmonary Vascular Disease
This is a observational、multicenter, prospective cohort study for patients with pulmonary hypertension (PH). The purposes of this study were to evaluate the etiology、clinical characteristics、treatment modalities, and outcomes of…
- Trial name
- NCPVD (NCT05368467)
- Testing
- The clinical course and disease management
- Where
- 13 sites in China
- Volunteers
- 1,000 people
- Sponsor
- Nanjing First Hospital, Nanjing Medical University
Pulmonary Vascular Disease, Pulmonary Artery Hypertension
HA Residents With PVD, 6MWD Assessed at HA (2840m) vs LA (Sea Level)
To study the effect of relocation from 2840m (Quito) to sea level (Pedernales) in patients with pulmonary vascular diseases (PVD) defined as pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension (PH)…
- Conditions
- Pulmonary Vascular Disease, Pulmonary Artery Hypertension, Chronic Thromboembolic Pulmonary Hypertension
- Trial name
- NCT05996302
- Testing
- Relocation to sea level
- Where
- Switzerland
- Volunteers
- 24 people
- Sponsor
- University of Zurich
Chronic Non-communicable Disease
Risk Factors at Chronic Non-communicable Diseases in People of Working Age
Objectives: to study the clinical and demographic characteristics of working age persons, to highlight the main factors of non-communicable diseases (NCDs), to identify NCDs with physical examination, laboratory tests…
- Trial name
- FORTUNE (NCT06812767)
- Testing
- electrocardiography, analysis for glucose and cholesterol in the capillary blood, detection of microalbumuria
- Where
- Russia
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- National Medical Research Center for Therapy and Preventive Medicine
Chronic Obstructive Pulmonary Disease, Hypertension, Pulmonary
Study of Dehydroepiandrosterone (DHEA) in Respiratory Pulmonary Hypertension in Adults
DHEA prevents and reverses chronic hypoxic pulmonary hypertension in a chronic hypoxic-pulmonary hypertension model in the rat. However, no study has been performed in human.
- Trial name
- DHEA-HTAP (NCT00581087)
- Testing
- DHEA treatment
- Where
- 5 sites in France
- Volunteers
- 60 people
- Sponsor
- University Hospital, Bordeaux
Juvenile Idiopathic Arthritis
Retrospective Analysis of Pulmonary Arterial Hypertension (PAH) and Related Complications in Juvenile Idiopathic Arthritis (JIA) Participants Treated With Biologic and Non-biologic Disease-modifying Anti-rheumatic Drugs (DMARDs)
This study is designed to analyze the frequency and incidence rate of pulmonary complications in JIA participants who received biological DMARDs and non-biologic DMARDs.
- Trial name
- NCT02784808
- Testing
- Biological DMARDs, Non-Biologic DMARDs
- Volunteers
- 4,557 people
- Sponsor
- Hoffmann-La Roche
PAH
CXA-10 Study in Subjects With Pulmonary Arterial Hypertension
This is a Phase 2, multicenter, open-label extension (OLE) of study CXA-10-301, to evaluate the long term safety and efficacy of daily dosing of CXA-10.
- Trial name
- NCT04053543
- Testing
- CXA-10
- Where
- 37 sites in United States, United Kingdom
- Volunteers
- 33 people
- Sponsor
- Complexa, Inc.
Pulmonary Arterial Hypertension
Study of ACT-293987 (NS-304) in Pulmonary Arterial Hypertension (PAH)
This is a multi-centre, multinational, open-label, single-dose acute hemodynamic study followed by randomized, double-blind, parallel-group, placebo controlled study.
- Trial name
- NCT00993408
- Testing
- ACT-293987 (NS-304)
- Where
- 8 sites in Austria, Belgium and 6 more
- Volunteers
- 43 people
- Sponsor
- Actelion
Reperfusion Pulmonary Edema
Evaluation of the Effectiveness of Non-invasive Ventilation on the Reperfusion Pulmonary Edema Post Pulmonary Artery Angioplasty in the Post Embolic Pulmonary Hypertension
The purpose of this study is to determine whether Non Invasive Ventilation are effective in prevention of reperfusion pulmonary edema after pulmonary artery angioplasty.
- Trial name
- OPR_VNI (NCT02548091)
- Testing
- Blood samples for assays of plasma inflammatory markers (cytokines InterLeukin-6, InterLeukin-8, InterLeukin-10), Non invasive ventilation, monitoring system Pulse-Induced Contour Cardiac Output (Picco)
- Where
- France
- Volunteers
- 236 people
- Sponsor
- Centre Chirurgical Marie Lannelongue
Pulmonary Hypertension
Exhaled Breath Olfactory Signature of Pulmonary Arterial Hypertension
In this prospective case-control study, the investigators will evaluate the diagnostic performance of a novel electronic nose (E-nose) for the detection of Pulmonary Arterial Hypertension (PAH). This study is designed to: 1.
- Trial name
- SNOOPY2 (NCT02782026)
- Testing
- Exhaled Breath Olfactory Signature (Artificial Nose)
- Where
- France
- Volunteers
- 273 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris